Recurrent miscarriage syndrome (RMS) is a common obstetric problem, affecting over 500,000 women in the United States per year (1); infertility, although less well defined in the population, is also a common clinical problem.
BLOOD COAGULATION PROTEIN/ PLATELET DEFECTS
RMS due to blood protein or platelet defects may come about through two mechanismsthose disorders associated with a hemorrhagic tendency or those defects associated with a thrombotic tendency. Hemorrhagic (bleeding) defects associated with RMS are very rare, while thrombotic or hypercoagulable/thrombophilic defects are extremely common (1, 2) . The hemorrhagic defects associated with fetal wastage syndrome presumably lead to inadequate fibrin formation, thus precluding adequate implantation of the fertilized ovum into the uterus. The hemorrhagic defects associated with fetal wastage syndrome include factor XIII deficiency (3) (4) (5) , factor XII defects (6) , factor X deficiency (7) , factor VII deficiency (8) , factor V deficiency (9) , factor II (prothrombin) deficiency (10) , von Willebrand syndrome, carriers of hemophilia and fibrinogen defects, including afibrinogenemia, those dysfibrinogenemias associated with hemorrhage and others (11) (12) (13) (14) (15) (16) (17) . Treatment of these patients is generally plasma substitution therapy or, in appropriate disorders, DDAVP therapy (1, 2) . Hemorrhagic/bleeding defects are rare causes of recurrent miscarriage as compared to thrombotic/thrombophilic disorders (1, 2) .
The thrombotic defects associated with fetal wastage are thought to occur due to thrombosis of early placental vessels, with peak fetal wastage in the first trimester, but small peaks also occur in the second and third trimesters (1, 2) . It appears the earlier the pregnancy, the smaller the placental and uterine vessels and, therefore, the greater the propensity to undergo partial or total occlusion by thrombus formation. Thrombotic occlusion of placental vessels, both venous and arterial, preclude adequate nutrition and, thus, viability of the fetus (1, 2) .
The thrombotic hemostasis defects associated with RMS include lupus anticoagulants and anticardiolipin antibodies (these two comprising the antiphospholipid syndromes associated with fetal wastage syndrome) (18) (19) (20) , factor XII deficiency (21) , dysfibrinogenemias associated with thrombosis (22) , protein C defects (23) , protein S defects, antithrombin deficiency (24) , heparin cofactor II deficiency (25) , and fibrinolytic defects associated with thrombosis, including plasminogen deficiency (26) , tissue plasminogen activator (t-PA) deficiency, elevated plasminogen activator inhibitor type 1 (PAI-1) (27) , and PAI-1 polymorphisms (28) . Although sticky platelet syndrome has been known for over a decade and leads to a variety of arterial and venous events, only recently has it become apparent that this de- fect is a common cause of RMS (2) and, like other new defects, including factor V Leiden, 5, 10-methyltetrahydrofolate reductase mutations (5,10-MTHFR) and prothrombin G20210A gene mutation, should be added to the prothrombotic disorders associated with RMS (2). It is anticipated that as new procoagulant factor mutations associated with hypercoagulability and thrombosis are discovered, they too will be found associated with placental thrombosis and RMS in many cases. Table 1 presents a summary of the bleeding disorders that may give rise to RMS or infertility; it should be appreciated these are very rare causes as compared to prothrombotic disorders. Table 2 summarizes the hypercoagulable, prothrombotic disorders leading to or potentially leading to RMS or infertility by inducing placental or uterine arterial or venous thrombosis; these defects are common causes of RMS and infertility.
PROCOAGULANT DEFECTS
The antiphospholipid syndrome is clearly the most common thrombotic defect leading to fetal wastage syndrome/infertility and a variety of treatment programs have been advocated. One difficulty in evaluating these has been that some populations have addressed primarily patients with secondary antiphospholipid syndrome and fetal wastage, in particular those with underlying systemic lupus erythematosus or other autoimmune disorders, and only a few investigators have addressed populations with primary antiphospholipid syndrome, with no known underlying disease.
Antiphospholipid syndrome (APLS) has long been recognized as a cause of miscarriage and infertility; it has long been recognized that treatment is often successful (29) . Many clinicians consider APLS to be the most common prothrombotic disorder among both hereditary and acquired defects and the most common thrombotic disorder causing recurrent miscarriage (1, 2, 18, 19, (30) (31) (32) (33) (34) . When assessing causes of infertility alone, APLS is thought to account for approximately 30% of infertility; however, in one series, abnormal CD 56+/CD 16 cell ratios were the single most common defect found (40%) in patients with infertility (35) . In another recent series, only 21% of patients with RMS had APLS; however, when assessing women with APLS historically, 80% had suffered at least one miscar-riage (36) . In a series reported by Granger, 384 unselected patients were assessed for APLS, of these 16% harbored APLS and of those with APLS 56% of APLS patients had a term delivery with low-dose aspirin (37) . Borelli found that 60% of patients with "habitual" unexplained miscarriage harbored APLS (38) . Although the great majority of cases of APLS are clearly acquired (32, 33) , familial APLS associated with RMS has been reported (39) . Clearly, however, screening for APLS is indicated in patients with RMS (1, 2, 18, 19, 30, 31, 33, 40) . One recent study has suggested that monitoring miscarriage patients with APLS by use of prothrombin fragment 1.2 may predict preclinical placental thrombi (41) ; if this is confirmed, it may preclude the necessity of frequent sonograms, which is our mode of observing pregnant RMS patients on therapy. In addition, because APLS is so common and many RECURRENT MISCARRIAGE SYNDROME 3 • Immune Vasculitis of the hereditary thrombophilias, such as factor V Leiden, are so prevalent in North America, it is not unexpected that some women with RMS will harbor APLS in combination with other procoagulant defects. Aznar has reported a case of RMS, complicated by deep venous thrombosis and thrombotic stroke in a patient with APLS, factor V Leiden, and congenital protein S deficiency (42) . Many proposed mechanisms whereby APLS interfere with the hemostasis system and predispose to thrombosis have been proposed. These are summarized in appropriate references (1, 2, 3, 18, 19, (30) (31) (32) (33) 40) . However, some investigators have proposed mechanisms specific for RMS. These proposed mechanisms have included that APLS induces acquired activated protein C resistance (APC-R) (43) , interference with prothrombin (factor II), protein C and protein S, tissue factor and factor XI (44) , and the tissue factor/tissue factor pathway inhibitor (TF/TFPI) system (45) . Another study also found that patients with APLS also harbored antibodies to prothrombin, protein C, and protein S (46) . Others have proposed these patients may also develop antibodies to "thromboplastin" and thrombin (47) . Another proposal is that antiphospholipid antibodies interfere with Annexin-V (also referred to as "placental anticoagulant protein") (48) . Two studies have shown Ig fractions of antiphospholipid antibody (APLA) or beta-2-glycoprotein-1 (APLA) decrease trophoblastic Annexin-V (48-50), but several have shown this anti-Annexin-V activity to be limited to the antiphosphatidlyserine subgroup antibody idiotype (51, 52) . However, two carefully performed studies have failed to demonstrate abnormalities of Annexin-V in miscarriage patients with APLS and concluded it plays no role in RMS (53, 54) . In an additional study of lupus patients, anti-annexin antibodies were detected in only 19%; however, these were not miscarriage patients (55) . In an additional study in non-RMS lupus patients, only 3.8% harbored anti-Annexin-V antibodies (44) . In yet another study, patients with thrombosis and APLS were assessed; only 8% harbored beta-2-glycoprotein-1 (56) . Testing for an antiphospholipid subgroup, in this case antiphosphatidylserine, was found useful in one study where RMS patients were negative for lupus anticoagulants and anticardiolipin antibodies; in this study, it was thought useful to test for this subgroup (57) . In another study, however, the use of APL subgroup testing was not considered helpful (58) . On rare occasions, antiphospholipid syndrome may be inherited (I have seen three such families) and others have been reported (39) , suggesting that a positive maternal history may warrant evaluation at first pregnancy, as should a history of familial thrombosis.
Patients harboring other congenital or acquired thrombophilic states are also at high risk for placental thrombosis and RMS. In one study assessing a variety of these defects in 46 selected women (anatomic and hormone defects ruled out before hemostasis assessment) with RMS the following were found: 76% had anticardiolipin antibodies (void of lupus anticoagulants) 3% had a lupus anticoagulant (void of anticardiolipin antibodies), 11% had congenital protein S deficiency (three quantitative and one dysfunctional), 6.5% had "sticky platelet syndrome" (two with type I and one with type II), 3% had dysfibrinogenemia, and 3% had congenital tPA deficiency (2) . In a study assessing prevalence of hereditary and acquired defects in RMS patients, 9% had isolated factor XII deficiency, 7.4% had antiphospholipid syndrome, and fibrinolytic system defects, leading to hypofibrinolysis and hypercoagulability were found in 43% of patients (59) . This study concluded von Willebrand's disease, fibrinogen deficiency, antithrombin deficiency, protein C and protein S deficiency, TPA deficiency, and PAI-1 defects played no role in RMS (59) . In a similar study assessing hereditary hemostasis defects in 125 RMS patients, quite different results were noted and factor V Leiden mutation was found in 14% (60) . However, in another study of 50 RMS patients, it was concluded that factor V Leiden, prothrombin G20210A mutation, and 5,10-methyltetrahydrofolate reductase mutations were not causes of RMS (61) . Factor V Leiden was discovered by Dahlback and associates in 1993 (62); thus, screening has only recently become common (62) . As noted previously, Kutteh failed to find an association between factor V Leiden and recurrent miscarriage; however, in a recent study factor V Leiden was responsible for 48% of recurrent miscarriages (63) . In another study of pregnancy, it was found that although factor V Leiden was responsible for a greater than threefold risk of deep venous thrombosis, there was no association with miscarriage (64) . In yet another study, however, factor V Leiden was associated with a high incidence of second trimester miscarriages (65) . Also, two additional studies have clearly shown an association between factor V Leiden mutation and recurrent miscarriages (66, 67) . Thus, the preponderance of current evidence certainly strongly suggests that heterozy-gous factor V Leiden mutation is a significant risk factor for recurrent miscarriage and increases the risk for miscarriage by at least 3.3-fold (63) . Another new common thrombophilic disorder, prothrombin G20210A gene mutation, was described by Poort and associates in 1996 (68) . Although Kutteh (61) found no association between this mutation and RMS, another study found an increased risk of recurrent miscarriage of 2.2-fold in women harboring this genetic procoagulant defect (69) . Another newly appreciated hereditary defect that leads to hypercoagulability and thrombosis is 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T mutation. One study found no association between this defect and recurrent miscarriage (61); however, another, more recent study, has shown a clear association between heterozygosity for this mutation and recurrent miscarriage with those harboring the mutation having a twofold enhanced risk (69) . Finally, although hypofibrinolysis, in general, has been shown to be associated with recurrent miscarriage (27) , only recently has the role of PAI-1 elevation and PAI-1 polymorphism(s) been shown as a cause of recurrent miscarriage syndrome (28) . Potential and proposed mechanism(s) of antiphospholipid antibody-induced thrombosis are summarized in Table 3 .
DALLAS THROMBOSIS HEMOSTASIS CLINICAL CENTER EXPERIENCE
Over the past 5 years we have carefully assessed 351 women referred for thrombosis and hemostasis evaluation after suffering recurrent miscariages. In the Dallas/Fort Worth Metroplex (DFW Metroplex), comprised of a population of approximately 6 million, a flow protocol is followed to maximize success and keep costs of evaluation for etiology of RMS/infertility at a minimum, while providing the best changes for defining an etiology and, thus, providing ideal therapy for successful term pregnancy outcome (1) (2) (3) . This protocol is presented in Fig. 2 . In all instances, women with RMS/infertility are first seen by an obstetrician or reproductive specialist; at this stage anatomic defects and hormonal defects are assessed and, if found, the workup stops at this point and treatment is initiated (approximately 25% of all women). If no anatomic or hormonal defect is found, the patient is then seen by referral for hemostasis evaluation; the positive yield among this selected population is approximately 92%. If this evaluation is negative (approximately 8%), then if the patient desires, chromosomal evaluation is initiated (approximately a 7% yield). Most of the obstetricians/reproductive specialists in the DFW metroplex refer after two or more miscarriages; however, some will refer after one miscarriage in the face of a positive family history for miscarriage and, occasionally, patients will request a workup after only one miscarriage; our practice has been to accommodate the desires of the patient, after discussing the costs and other implications of evaluation. At this time, all 322 patients with a defect have been observed for at least 15 months, thus have been analyzed in detail and are presented below. 
CHARACTERISTICS OF THE FIRST 351 WOMEN REFERRED FOR HEMOSTASIS EVALUATION
The mean age of patients referred for a hemostasis evaluation is 33.3, the mean number of miscarriages before referral is 2.9 (range, 2 to 9) and the percent found with a hemostasis defect has been 92%. This information is provided in Table 4 .
All patients underwent a thorough evaluation for thrombophilia and, when indicated, a hemorrhagic disorder. Of the 351 patients, 29 (8%) had no defect. Of the remaining 322 patients, seven (2%) had a bleeding disorder: three with platelet dysfunction, one with factor XIII deficiency, three with von Willebrand, and three with Osler-Weber-Rendu. The remainder of the patients had a thrombophilia as follows: 195 (60%) had antiphospholipid syndrome, 64 (20%) had sticky platelet syndrome, 38 (12%) had MTHFR mutation, 23 (7.1%) had PAI-1 polymorphism, 12 (3.7%) had protein S deficiency, 12 (3.7%) had factor V Leiden, 3 (1%), had AT deficiency, 3 (1%) had heparin-cofactor II deficiency, 3 (1%) had TPA deficiency, and 6 (2%) had protein C deficiency. There were a total of 364 defects found in the 312 patients harboring thrombophilia; thus, several harbored two and a few harbored three separate defects.
Like that found by most other investigators, discussed previously, the most common defect found has been APLS; however, unlike some groups, we assess for all phospholipid antibody subgroups including antiphosphatidylserine, an- tiphosphatidylethanolamine, antiphosphatidylglycerol, antiphosphatidic acid, antiphosphatidylcholine, antiphosphatidylinositol, anti-Annexin-V antibody, beta-2-glycoprotein-1, hexagonal phospholipid, and lupus anticoagulant (by dRVVT with correction by non-platelet-derived phospholipid to avoid false-positive results). We always assess all three idiotypes of anticardiolipin antibody (IgG, IgA, and IgM); an incomplete evaluation continues to be made by many who evaluate these patients and leave out either IgA or IgM idiotypes. The most common defect we find is antiphospholipid syndrome, followed by sticky platelet syndrome (SPS), followed by MTHFR mutations, PAI-1 defects-most commonly polymorphisns (4G/5G or 4G/4G), protein S deficiency, factor V Leiden, antithrombin deficiency, heparin co-factor II deficiency, tissue plasminogen activator (tPA) defects, and protein C deficiency. It is of interest that by including all antiphospholipid subgroups, it is found that 29% of patients have a subgroup antiphospholipid antibody, but no anticardiolipin antibody or lupus anticoagulant; thus, 29% of patients would remain undiagnosed if these subgroups are not performed. Interestingly, this is about the same finding recently noted in young age (<51 years) thrombotic stroke patients (70) . The hemostasis defects found in our population are summarized in Table 5 . The particulars of the antiphospholipid patients, with demonstration of the idiotypes found, are summarized in Table 6 . All patients with a thrombophilic defect were treated with preconception aspirin at 81 mg/day and, at documentation of conception, were treated with the addition of subcutaneous unfractionated porcine mucosal heparin at 5000 units every 12 hours by self-injection (first 120 patients) or subcutaneous low-molecular-weight (LMW) heparin dalterparin (Fragmin) at 5000 units every 24 hours by self-injection (subsequent 192 patients). Both drugs (aspirin + unfractionated heparin or LMW heparin) are used to term. All patients are instructed in heparin injections and are informed of all important side effects of heparin therapy and are extensively informed of the benefits and risks of heparin / LMW heparin therapy, including the fact that side effects, although rare, include heparin-induced thrombocytopenia (HIT) with and without paradoxical thrombosis/thromboembolism (HITT); osteoporosis; mild-to-moderate alopecia; skin and allergic reactions, including erythema and itching, at injection sites; eosinophilia (of little clinical consequence); and potential bleeding. Patients are also informed that a transient transaminasemia develops in approximately 5% to 10% of patients during heparin/LMW heparin therapy, but this is without any known adverse clinical consequences. They are also instructed that the ideal injection sites are the anterior or lateral thighs, injection sites should be rotated with every injection, each injection is likely to produce a bruise of approximately 0.5 to 4.0 cm in diame-RECURRENT MISCARRIAGE SYNDROME 7 ter, and pain of injection, if experienced, can usually be alleviated by applying a small piece of ice at the site for 20 seconds before and 20 seconds after the injection is given. All patients are instructed to return immediately if they note dark or black areas of the injection site, potentially indicative of skin necrosis. The methods of followup are summarized in Table 7 . Cases of prosthetic heart valve thrombosis have been reported in patients with prosthetic valves who have received enoxaparin for thromboprophylaxis. Some of these cases were pregnant women in whom thrombosis led to maternal deaths and fetal deaths. Pregnant women with prosthetic heart valves may be at higher risk for thromboembolism (see PRECAUTIONS: Pregnancy).
PRECAUTIONS Pregnancy

Teratogenic Effects
Second paragraph added:
There have been reports of congenital anomalies in infants born to women who received enoxaparin during pregnancy including cerebral anomalies, limb anomalies, hypospadias, peripheral vascular malformation, fibrotic dysplasia, and cardiac defect. A cause and effect relationship has not been established nor has the incidence been shown to be higher than in the general population. 
Non-Teratogenic Effects
First paragraph revised:
There have been post-marketing reports of fetal death when pregnant women received Lovenox Injection. Causality for these cases has not been determined. Pregnant women receiving anti-coagulants, including enoxaparin, are at increased risk for bleeding. Hemorrhage can occur at any site and may lead to death of mother and/or fetus. Pregnant women receiving enoxaparin should be carefully monitored. Pregnant women and women of child-bearing potential should be apprised of the potential hazard to the fetus and the mother if enoxaparin is administered during pregnancy.
Second paragraph added:
In a clinical study of pregnant women with prosthetic heart valves given enoxaparin (1 mg/kg bid) to reduce the risk of thromboembolism, 2 of 7 women developed clots resulting in blockage of the valve and leading to maternal and fetal death. There are postmarketing reports of prosthetic valve thrombosis in pregnant women with prosthetic heart valves while receiving enoxaparin for thromboprophylaxis. These events resulted in maternal death or surgical interventions. The use of Lovenox Injection is not recommended for thromboprophylaxis in pregnant women with prosthetic heart valves (see WARNINGS: Prosthetic Heart Valves).
ADVERSE REACTIONS
Ongoing Safety Surveillance: Since 1993, there have been over 80 reports of epidural or spinal hematoma formation with concurrent use of Lovenox Injection and spinal/epidural anesthesia or spinal puncture OUTCOMES All of the 315 patients with a thrombophilic defect were treated with the aforementioned regimen of preconception low-dose aspirin plus addition of postconception thromboprophylactic (low-dose) subcutaneous porcine heparin or thromboprophylactic doses of dalteparin. Patients with MTHFR mutations were also treated with folic acid at 5 mg/day plus pyridoxine at 50 mg/day. There were a total of four miscarriages (2.6%); only two were treatment failures.
One loss was during the second trimester and accompanied a cholycystectomy and one loss was during the first trimester in an individual with APLS and a fetal chromosomal defect; these were not considered treatment (aspirin + heparin/ LMW heparin) failures. However, two patients suffered loss, both first trimester, on aspirin + heparin/LMW heparin and placental thrombi and infarcts were present; thus, there were two losses that clearly represented treatment failure. The overall success in treating RMS patients with procoagulant/platelet defects in our program is, therefore, 99% (312/315) with respect to normal term delivery. All patients were observed for a minimum of 3 months after delivery. No patient sustained a thrombotic episode during pregnancy, delivery, or post-partum, except the two treatment failures, both of whom had placental vascular thrombi. In addition, HIT/T did not develop, nor did a clinically significant hemorrhage. Small ecchymoses at injection sites developed in almost all patients, but these were considered insignificant by both the patient and physician. Eosinophilia developed in 10% of patients that abated by 3 months post-partum, and mild-to-moderate elevations of hepatic transaminases developed in 7%; these also returned to normal by 3 months post-partum. As per obstetricians, reproductive medicine specialists, and involved pediatricians, no neonatal or pediatric problems were associated with therapy. No patient sustained a fracture during or after treatment.
Patients with a bleeding disorder (n = 7) were untreated. No patient experienced significant hemorrhage during pregnancy or delivery. None required blood product therapy.
TREATMENT REVIEW
Because fetal loss associated with bleeding disorders is thought to come about due to interference with adequate fibrin formation for implantation of the fertilized ovum into the uterine lining, we chose to not use vigorous pre-conception antithrombotic therapy with those with thrombophilia and used low-dose aspirin at 81 mg/day; this may be of theoretical concern only, in view of the recent report of Sher who used pre-conception low-dose heparin with a high success rate for in vitro fertilization techniques (71) . However, we remain concerned and continue to advocate low-dose aspirin as the pre-conception antithrombotic therapy in most instances (1, 2, 4) .
The regimen of post-conception addition of fixed low-dose porcine mucosal heparin at 5000 units every 12 hours is empirical, but higher doses seem to be associated with bleeding and a lower success rate (48, 72) . However, it may be that even lower doses might suffice. We do not advocate using corticosteroid therapy in this population, based on the negative experience of others in fetal wastage syndrome, and our preliminary experience of using steroids, in conjunction with antithrombotics, in patients with antiphospholipid syndrome and other types of thrombosis, wherein the corticosteroid use could be shown to lower antiphospholipid antibody titers, but failed to abort thrombotic events (1, 2, 18, 19, (31) (32) (33) . In addition, it is thought steroid use in patients with APLS may be detrimental (29) .
A variety of treatment programs have been used for women with antiphospholipid (anticardiolipin antibodies or lupus anticoagulants) and fetal wastage syndrome; however, many of these studies have studied only very small populations, or fail to distinguish between primary or secondary antiphospholipid syndrome in the information provided. Brown (73) reported a 90% failure rate (miscarriage) among untreated women, Perino (74) reports a 93% failure rate in untreated women and Many (75) reports a 93% failure rate in untreated patients. Lubbe (76) , in a small group of women, noted a successful term pregnancy rate of 80% with use of prednisone and aspirin, and a similar success rate with this regimen was noted by Lin (77) . Cowchuck (78) noted a 75% success rate with prednisone alone or aspirin alone, but also noted more undesirable effects in the prednisone-treated population. Landy (79) , in a small population, reported a success rate of 90% with either aspirin alone or prednisone alone. However, Many (75) only noted a 43% successful term pregnancy rate with aspirin and prednisone and Semprini (80) noted only a 14% success rate with prednisone alone. Several studies have assessed the role of the post-conception addition of heparin; however, most have used higher doses than those used in our population. Rosove (72) reports a 93% success rate with dose-adjusted subcutaneous heparin, the mean heparin doses being approximately 25,000 U/day. Kuttah (81) , in a population of 25 patients treated with aspirin plus doseadjusted subcutaneous heparin, noted a success rate of 76%; the mean heparin dose was 26,000 U/day. In Many's study (75) , patients treated with prednisone plus aspirin plus heparin at 5000 units twice a day had a better outcome (69%) than did those treated with aspirin plus prednisone (43%) or prednisone alone (7%). Based on our original and current results (1, 2) , it appears that fixed low-dose porcine heparin is more effective than the high-dose, dose-adjusted regimens, with greater than 98% of our RMS population with antiphospholipid syndrome or other prothrombotic propensity having a normal term delivery. It may be that higher doses of heparin somehow contribute to adverse outcomes, such as small periplacental hemorrhages. Parke (82) reports on the combination of low-dose heparin used in conjunction with intravenous immunoglobulin; her success rate, however, was only 27%, suggesting that intravenous immunoglobulin has little role in antiphospholipid fetal wastage syndrome.
SUMMARY
Recurrent miscarriage syndrome and infertility are common problems in the United States, with recurrent miscarriage affecting more than 500,000 women annually. If properly screened through a cost-effective protocol as outlined previously, the etiology will be found in almost all women. The most common singular defect in women with RMS is a hemostasis defect and the most common of these is APLS, if a thorough APLS evaluation is performed. Following APLS, other hereditary and acquired procoagulant defects are also commonly found if sought. It is important to appropriately evaluate women with RMS because if a cause is found, the majority will have positive outcomes with normal term delivery. Hemorrhagic defects are very rare hemostasis causes of RMS, but are treatable in many instances and should be sought in appropriate women. Treatment of the common procoagulant defects consists of preconception low-dose aspirin at 81 mg/day followed by addition of immediate postconception low-dose unfractionated porcine heparin or dalteparin. Based on our experience, low-molecular-weight heparin may be a suitable alternative.
